We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Blood Test Predicts Effectiveness of Depression Medication

By LabMedica International staff writers
Posted on 13 Apr 2017
Print article
Image: Professor Madhukar Trivedi (front) demonstrated that measuring a depressed patient’s C-reactive protein level can help doctors prescribe an antidepressant that is more likely to work (Photo courtesy of UT Southwestern Medical Center).
Image: Professor Madhukar Trivedi (front) demonstrated that measuring a depressed patient’s C-reactive protein level can help doctors prescribe an antidepressant that is more likely to work (Photo courtesy of UT Southwestern Medical Center).
Depression and anxiety are two important mood disorders that are frequently associated with chronic diseases such as cardiovascular diseases (CVDs). Hyper-inflammation is related to both CVDs and psychological conditions such as depression and anxiety.

A finger-prick blood test could help doctors to choose which medication is most likely to succeed in treating depression as levels of C-reactive protein in the blood predict which antidepressant treatments are most likely to lead to successful outcomes in patients with depression.

Scientists at the University of Texas Southwestern Medical Center and their colleagues analyzed remission rates in 106 patients with depression who were randomly allocated between two groups. One group of 51 patients was prescribed the selective serotonin reuptake inhibitor escitalopram alone and 55 patients in the other group were prescribed escitalopram plus bupropion.

C-reactive protein (CRP), serum amyloid P component, and alpha-2-macroglobulin were measured using the Bioplex Pro human acute-phase 4-plex panel. The reason CRP was chosen was because it is often used as a marker of inflammation in cardiovascular disease, diabetes, and other disorders.

The team found that the treatment arms did not differ in depressive symptom or side effect outcomes. Most participants 74/106 (69.8%) had baseline CRP levels greater than 1 mg/L (indicative of systemic inflammatory activity). Higher baseline CRP levels were associated lower depression severity with bupropion-SSRI combination but not with SSRI monotherapy. The overall remission rate was 41.5%. The estimated remission rate with CRP threshold based assignment (SSRI monotherapy for less than 1 mg/L and Bupropion-SSRI for equal to or greater than 1 mg/L) was 53.1%. Side effect burden was unrelated to any baseline inflammatory marker.

Madhukar Trivedi, MD, a professor and senior author of the study, said, “Both patients and primary-care providers are very desperately looking for markers that would indicate there is some biology involved in this disease. Otherwise, we are talking about deciding treatments from question-and-answer from the patients, and that is not sufficient.” The study was published in the April 2017 edition of the journal Psychoneuroendocrinology.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.